Malcolm Lader

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11890747/publications.pdf

Version: 2024-02-01

99 papers 6,692 citations

76326 40 h-index 81 g-index

143 all docs

143
docs citations

times ranked

143

4819 citing authors

#	Article	IF	CITATIONS
1	The use of analogue scales in rating subjective feelings. The British Journal of Medical Psychology, 1974, 47, 211-218.	0.5	1,692
2	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. World Journal of Biological Psychiatry, 2008, 9, 248-312.	2.6	661
3	Benzodiazepines revisited—will we ever learn?. Addiction, 2011, 106, 2086-2109.	3.3	414
4	Withdrawing Benzodiazepines in Primary Care. CNS Drugs, 2009, 23, 19-34.	5.9	255
5	Benzodiazepine harm: how can it be reduced?. British Journal of Clinical Pharmacology, 2014, 77, 295-301.	2.4	225
6	Cognitive impairment in long-term benzodiazepine users. Psychological Medicine, 1988, 18, 365-374.	4.5	155
7	Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety, 2004, 19, 241-248.	4.1	140
8	Physiological changes during spontaneous panic attacks. Journal of Psychosomatic Research, 1970, 14, 377-382.	2.6	134
9	Usage of benzodiazepines: A review. International Journal of Psychiatry in Clinical Practice, 2010, 14, 78-87.	2.4	121
10	Benzodiazepine Withdrawal Phenomena. International Pharmacopsychiatry, 1981, 16, 235-244.	0.4	116
11	Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology, 1991, 103, 83-90.	3.1	115
12	The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects. Psychopharmacology, 1986, 89, 395-403.	3.1	97
13	Discontinuation symptoms in depression and anxiety disorders. International Journal of Neuropsychopharmacology, 2007, 10, 73.	2.1	97
14	Post-Mortem Antipsychotic Drug Concentrations and Unexplained Deaths. British Journal of Psychiatry, 1994, 165, 787-791.	2.8	87
15	Anxiolytic drugs: dependence, addiction and abuse. European Neuropsychopharmacology, 1994, 4, 85-91.	0.7	81
16	Atypical Antipsychotics. Drug Safety, 2005, 28, 35-51.	3.2	81
17	History of benzodiazepine dependence. Journal of Substance Abuse Treatment, 1991, 8, 53-59.	2.8	80
18	The influences of age and caffeine on psychomotor and cognitive function. Psychopharmacology, 1999, 145, 181-188.	3.1	80

#	Article	IF	CITATIONS
19	A method to elicit aggressive feelings and behaviour via provocation. Biological Psychology, 1986, 22, 69-79.	2.2	76
20	A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology, 2015, 5, 357-368.	2.7	71
21	Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology, 1988, 95, 520-7.	3.1	69
22	Benzodiazepine problems. Addiction, 1991, 86, 823-828.	3.3	69
23	Selective attention and "habituation―of the auditory averaged evoked response in humans. Physiology and Behavior, 1972, 8, 79-85.	2.1	68
24	Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychological Medicine, 1984, 14, 937-940.	4.5	66
25	Rebound insomnia and newer hypnotics. Psychopharmacology, 1992, 108, 248-255.	3.1	66
26	A Comparison of Buspirone and Placebo in Relieving Benzodiazepine Withdrawal Symptoms. Journal of Clinical Psychopharmacology, 1987, 7, 11???15.	1.4	63
27	The biological basis of benzodiazepine dependence. Psychological Medicine, 1987, 17, 539-547.	4.5	62
28	Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology, 1994, 114, 187-189.	3.1	58
29	The Peripheral and Central Role of the Catecholamines in the Mechanisms of Anxiety. International Pharmacopsychiatry, 1974, 9, 125-137.	0.4	57
30	Effectiveness of benzodiazepines: do they work or not?. Expert Review of Neurotherapeutics, 2008, 8, 1189-1191.	2.8	56
31	Zopiclone: Is there any dependence and abuse potential?. Journal of Neurology, 1997, 244, S18-S22.	3.6	53
32	Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Current Psychiatry Reports, 2016, 18, 8.	4.5	52
33	Stress and age effects on catecholamines in normal subjects. Journal of Psychosomatic Research, 1981, 25, 33-41.	2.6	48
34	Limitations of current medical treatments for depression: Disturbed circadian rhythms as a possible therapeutic target. European Neuropsychopharmacology, 2007, 17, 743-755.	0.7	47
35	The Relationship Between Induced Behavioural Aggression and Mood after the Consumption of Two Doses of Alcohol. Addiction, 1986, 81, 65-75.	3.3	46
36	A followâ€up study of patients treated for benzodiazepine dependence. The British Journal of Medical Psychology, 1987, 60, 141-149.	0.5	45

#	Article	IF	Citations
37	Rational Use of Anxiolytic/Sedative Drugs. Drugs, 1983, 25, 514-528.	10.9	44
38	Differential effects of oxazepam and lorazepam on aggressive responding. Psychopharmacology, 1988, 95, 369-73.	3.1	42
39	Escitalopram in the treatment of social anxiety disorder: Analysis of efficacy for different clinical subgroups and symptom dimensions. Depression and Anxiety, 2004, 20, 175-181.	4.1	42
40	Systemic absorption and abuse liability of snorted flunitrazepam. Addiction, 1994, 89, 821-830.	3.3	41
41	Antiparkinsonian Medication and Pathological Gambling. CNS Drugs, 2008, 22, 407-416.	5.9	40
42	Group Treatment of Benzodiazepine Dependence. Addiction, 1987, 82, 517-532.	3.3	38
43	Guidelines for the prevention and treatment of benzodiazepine dependence: summary of a report from the Mental Health Foundation. Addiction, 1993, 88, 1707-1708.	3.3	36
44	Effects of attention, activation and stimulus regularity on short-term â€~habituation' of the averaged evoked response. Biological Psychology, 1975, 3, 57-69.	2.2	34
45	Sleep Studies and Rebound Insomnia. Clinical Neuropharmacology, 1987, 10, 291-312.	0.7	32
46	Pharmacotherapy of Mood Disorders and Treatment Discontinuation. Drugs, 2007, 67, 1657-1663.	10.9	30
47	Ambulatory Electrodermal Monitoring: Effects of Ambient Temperature, General Activity, Electrolyte Media, and Length of Recording. Psychophysiology, 1983, 20, 219-224.	2.4	29
48	Salivary secretion and depressive illness: a physiological and psychometric study. Psychological Medicine, 1971, 1, 372-376.	4.5	27
49	Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation. Psychopharmacology, 1986, 89, 360-3.	3.1	27
50	Do scopolamine and lorazepam have dissociable effects on human memory systems? A dose–response study with normal volunteers Experimental and Clinical Psychopharmacology, 1996, 4, 292-299.	1.8	27
51	Fluoxetine Efficacy vs Comparative Drugs: An Overview. British Journal of Psychiatry, 1988, 153, 51-58.	2.8	26
52	A Physiological Comparison of â€~Endogenous' and â€~Reactive' Depression. British Journal of Psychiatry, 1972, 120, 541-542.	2.8	25
53	Dream content and daytime attitudes in anxious and calm women. Psychological Medicine, 1978, 8, 297-304.	4.5	25
54	Anxiety or depression during withdrawal of hypnotic treatments. Journal of Psychosomatic Research, 1994, 38, 113-123.	2.6	24

#	Article	IF	Citations
55	Withdrawal Reactions after Stopping Hypnotics in Patients with Insomnia. CNS Drugs, 1998, 10, 425-440.	5.9	24
56	Can Buspirone Induce Rebound, Dependence or Abuse?. British Journal of Psychiatry, 1991, 159, 45-51.	2.8	23
57	Biological processes in benzodiazepine dependence. Addiction, 1994, 89, 1413-1418.	3.3	22
58	Computed axial brain tomograms in long-term benzodiazepine users. Psychiatry Research, 1993, 48, 135-144.	3.3	19
59	A Criticism of the Practice of Prescribing Subtherapeutic Doses of Antidepressants for the Treatment of Depression. Human Psychopharmacology, 1996, 11, 283-291.	1.5	19
60	Prolactin and psychophysiologic measures after single doses of thioridazine. Clinical Pharmacology and Therapeutics, 1977, 21, 422-429.	4.7	18
61	Regular interstimulus interval as a critical determinant of short-term "habituation―of the auditory averaged evoked response. Learning and Behavior, 1972, 27, 275-278.	0.6	17
62	Differential effects of flumazenil in alcoholic and nonalcoholic cirrhotic patients. Psychopharmacology, 1995, 120, 220-226.	3.1	17
63	Management of panic disorder. Expert Review of Neurotherapeutics, 2005, 5, 259-266.	2.8	16
64	Antianxiety Drugs, 1976, 12, 362-373.	10.9	15
65	Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions. European Neuropsychopharmacology, 2006, 16, 33-38.	0.7	15
66	Benzodiazepine Dependence. International Review of Psychiatry, 1989, 1, 149-156.	2.8	14
67	Concomitant short-term changes in the auditory evoked response, the EEG, and reaction-time performance in relation to the temporal parameters of stimulation. Scandinavian Journal of Psychology, 1975, 16, 177-183.	1.5	13
68	Rating Scales in Schizophrenia. CNS Drugs, 2000, 14, 23-32.	5.9	13
69	Self-concepts in anxiety states. The British Journal of Medical Psychology, 1976, 49, 275-279.	0.5	11
70	Short-term versus long-term benzodiazepine therapy. Current Medical Research and Opinion, 1984, 8, 120-126.	1.9	9
71	DEPENDENCE AND WITHDRAWAL: COMPARISON OF THE BENZODIAZEPINES AND SELECTIVE SEROTONIN REâ€UPTAKE INHIBITORS. Addiction, 2012, 107, 909-910.	3.3	9
72	Comparative amnesic and sedative effects of lorazepam and oxazepam in healthy volunteers. Journal of Psychopharmacology, 1993, 7, 249-256.	4.0	8

#	Article	IF	CITATIONS
73	Benzodiazepines â€" Panacea or Poison?. Australian and New Zealand Journal of Psychiatry, 1981, 15, 1-9.	2.3	7
74	Lack of effect of a small dose of flumazenil in reversing short-term tolerance to benzodiazepines in normal subjects. Journal of Psychopharmacology, 1991, 5, 220-227.	4.0	7
75	Psychophysiological Research and Psychosomatic Medicine. Novartis Foundation Symposium, 1972, 8, 297-320.	1.1	7
76	Clozapine - A Summary. British Journal of Psychiatry, 1992, 160, 65-66.	2.8	6
77	The Nature of Clinical Anxiety in Modern Society. Issues in Mental Health Nursing, 1985, 7, 309-334.	1.2	5
78	[Commentary] COMING OFF TRANQUILLIZERS—A SISYPHEAN TOIL. Addiction, 2009, 104, 25-26.	3.3	5
79	Effects of Clorazepate Dipotassium and Placebo on Psychomotor Skills. Perceptual and Motor Skills, 1985, 61, 1121-1122.	1.3	4
80	The return of L-tryptophan: Introduction. Human Psychopharmacology, 1994, 9, 365-366.	1.5	4
81	SYMPOSIUM SUMMARY. British Journal of Clinical Pharmacology, 1979, 8, 81S.	2.4	3
82	The Use of Digital Techniques in Psychophysiological Research. Psychophysiology, 1974, 11, 372-381.	2.4	2
83	Institute of Psychiatry Clinical Psychopharmacology Research Team. Psychological Medicine, 1974, 4, 110-116.	4.5	2
84	Treatment-resistant schizophrenia. Tetrabenazine and Reserpine: A case-study. Journal of Forensic Psychiatry Psychology, 1998, 9, 440-445.	0.3	2
85	Sleep Disorders— Therapeutic Armamentarium. , 0, , 1307-1314.		2
86	A NICE missed opportunity?. Journal of Psychopharmacology, 2005, 19, 136-138.	4.0	2
87	Benzodiazepine withdrawal syndrome. British Journal of Psychiatry, 1991, 158, 435-436.	2.8	1
88	A patient who changed my practice: Personality disorder or bipolar disorder?. International Journal of Psychiatry in Clinical Practice, 1998, 2, 67-68.	2.4	1
89	Long-Term Side-Effects of Antipsychotic Drug Medication. AVMA Medical & Legal Journal, 1998, 4, 173-177.	0.1	1
90	Anxiolytics and Sedatives., 2012,, 231-239.		1

#	Article	IF	Citations
91	The Nature of Anxiety. British Journal of Psychiatry, 1972, 120, 573-573.	2.8	O
92	Bio-psycho-social interactions in anxiety and panic disorders: a speculative perspective. Irish Journal of Psychological Medicine, 1991, 8, 154-159.	1.0	0
93	Psychopharmacology of Panic. Edited By Stuart Montgomery. Oxford: Oxford University Press. 1993. 149 pp. £22.99 British Journal of Psychiatry, 1994, 164, 570-571.	2.8	O
94	Anxiolytic effect of hydroxyzine: a double-blind trial versus placebo and buspirone. Human Psychopharmacology, 1999, 14, S94-S102.	1.5	O
95	Lethal complications of antipsychotic drug medication. Clinical Risk, 2006, 12, 113-117.	0.1	O
96	Foreword. Clinical Drug Investigation, 2011, 31, 1-3.	2.2	0
97	Psychopharmacology of Panic. Edited By Stuart Montgomery. Oxford: Oxford University Press. 1993. 149 pp. £22.99 British Journal of Psychiatry, 1994, 164, 570-571.	2.8	0
98	Selective Serotonin Re-Uptake Inhibitors By J. P. Feighner. W. F. Boyer. Chichester: John Wiley. 1996. 373 pp. £50.00 (hb). British Journal of Psychiatry, 1997, 170, 487-487.	2.8	0
99	Classification and drug treatment of the anxiety disorders. Psychiatria Et Neurologia Japonica - Seishin Shinkeigaku Zasshi, 2004, 106, 1242-53.	0.1	O